<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33096857</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2072-6651</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>10</Issue><PubDate><Year>2020</Year><Month>Oct</Month><Day>21</Day></PubDate></JournalIssue><Title>Toxins</Title><ISOAbbreviation>Toxins (Basel)</ISOAbbreviation></Journal><ArticleTitle>Neurotrophic Properties of C-Terminal Domain of the Heavy Chain of Tetanus Toxin on Motor Neuron Disease.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">666</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/toxins12100666</ELocationID><Abstract><AbstractText>The carboxyl-terminal domain of the heavy chain of tetanus toxin (Hc-TeTx) exerts a neuroprotective effect in neurodegenerative diseases via the activation of signaling pathways related to neurotrophins, and also through inhibiting apoptotic cell death. Here, we demonstrate that Hc-TeTx preserves motoneurons from chronic excitotoxicity in an in vitro model of amyotrophic lateral sclerosis. Furthermore, we found that PI3-K/Akt pathway, but not p21ras/MAPK pathway, is involved in their beneficial effects under chronic excitotoxicity. Moreover, we corroborate the capacity of the Hc-TeTx to be transported retrogradely into the spinal motor neurons and also its capacity to bind to the motoneuron-like cell line NSC-34. These findings suggest a possible therapeutic tool to improve motoneuron preservation in neurodegenerative diseases such as amyotrophic lateral sclerosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Herrando-Grabulosa</LastName><ForeName>Mireia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Neurosciences, Department of Biochemistry and Molecular Biology, Universitat Aut&#xf2;noma de Barcelona, 08193 Cerdanyola del Vall&#xe8;s, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casas</LastName><ForeName>Caty</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-2273-6321</Identifier><AffiliationInfo><Affiliation>Institute of Neurosciences, Department of Cell Biology, Physiology and Immunology, Universitat Aut&#xf2;noma de Barcelona, 08193 Cerdanyola del Vall&#xe8;s, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talbot</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-5490-1697</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford OX3 9DU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aguilera</LastName><ForeName>Jos&#xe9;</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Neurosciences, Department of Biochemistry and Molecular Biology, Universitat Aut&#xf2;noma de Barcelona, 08193 Cerdanyola del Vall&#xe8;s, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>SAF2013-43900-R</GrantID><Agency>Ministerio de Ciencia e Innovaci&#xf3;n</Agency><Country>International</Country></Grant><Grant><GrantID>SAF2016-8027-R</GrantID><Agency>Ministerior de Ciencia e Innovaci&#xf3;n</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Toxins (Basel)</MedlineTA><NlmUniqueID>101530765</NlmUniqueID><ISSNLinking>2072-6651</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013744">Tetanus Toxin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C040635">tetanus toxin fragment C</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.137</RegistryNumber><NameOfSubstance UI="D058539">Phosphatidylinositol 3-Kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058539" MajorTopicYN="N">Phosphatidylinositol 3-Kinase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072417" MajorTopicYN="N">Protein Domains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013744" MajorTopicYN="N">Tetanus Toxin</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046509" MajorTopicYN="N">Tissue Culture Techniques</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">carboxyl-terminal domain of the heavy chain of tetanus toxin</Keyword><Keyword MajorTopicYN="N">excitotoxicity</Keyword><Keyword MajorTopicYN="N">neuroprotection</Keyword><Keyword MajorTopicYN="N">spinal muscular atrophy</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>24</Day><Hour>1</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33096857</ArticleId><ArticleId IdType="pmc">PMC7589688</ArticleId><ArticleId IdType="doi">10.3390/toxins12100666</ArticleId><ArticleId IdType="pii">toxins12100666</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wijesekera L.C., Leigh P.N. Amyotrophic lateral sclerosis. Orphanet J. Rare Dis. 2009;4:3. doi: 10.1186/1750-1172-4-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1172-4-3</ArticleId><ArticleId IdType="pmc">PMC2656493</ArticleId><ArticleId IdType="pubmed">19192301</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A.C., Jesse S. Evidence-based drug treatment in amyotrophic lateral sclerosis and upcoming clinical trials. Ther. Adv. Neurol. Disord. 2009;2:319&#x2013;326. doi: 10.1177/1756285609336399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756285609336399</ArticleId><ArticleId IdType="pmc">PMC3002601</ArticleId><ArticleId IdType="pubmed">21180622</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K., Aoki M., Tsuji S., Itoyama Y., Sobue G., Togo M., Hamada C., Tanaka M., Akimoto M., Nakamura K., et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505&#x2013;512. doi: 10.1016/S1474-4422(17)30115-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbot K., Feneberg E., Scaber J., Thompson A.G., Turner M.R. Amyotrophic lateral sclerosis: The complex path to precision medicine. J. Neurol. 2018;265:2454&#x2013;2462. doi: 10.1007/s00415-018-8983-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-8983-8</ArticleId><ArticleId IdType="pmc">PMC6182683</ArticleId><ArticleId IdType="pubmed">30054789</ArticleId></ArticleIdList></Reference><Reference><Citation>Bizzini B., Stoeckel K., Schwab M. An antigenic polypeptide fragment isolated from tetanus toxin: Chemical characterization, binding to gangliosides and retrograde axonal transport in various neuron systems. J. Neurochem. 1977;28:529&#x2013;542. doi: 10.1111/j.1471-4159.1977.tb10423.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.1977.tb10423.x</ArticleId><ArticleId IdType="pubmed">67185</ArticleId></ArticleIdList></Reference><Reference><Citation>Manning K.A., Erichsen J.T., Evinger C. Retrograde transneuronal transport properties of fragment C of tetanus toxin. Neuroscience. 1990;34:251&#x2013;263. doi: 10.1016/0306-4522(90)90319-Y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0306-4522(90)90319-Y</ArticleId><ArticleId IdType="pubmed">1691466</ArticleId></ArticleIdList></Reference><Reference><Citation>Price D.L., Griffin J., Young A., Peck K., Stocks A. Tetanus toxin: Direct evidence for retrograde intraaxonal transport. Science. 1975;30:945&#x2013;947. doi: 10.1126/science.49080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.49080</ArticleId><ArticleId IdType="pubmed">49080</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalli G., Schiavo G. Analysis of retrograde transport in motor neurons reveals common endocytic carriers for tetanus toxin and neurotrophin receptor p75NTR. J. Cell Biol. 2002;156:233&#x2013;239. doi: 10.1083/jcb.200106142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200106142</ArticleId><ArticleId IdType="pmc">PMC2199221</ArticleId><ArticleId IdType="pubmed">11807088</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalli G., Bohnert S., Deinhardt K., Verastegui C., Schiavo G. The journey of tetanus and botulinum neurotoxins in neurons. Trends Microbiol. 2003;11:431&#x2013;437. doi: 10.1016/S0966-842X(03)00210-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0966-842X(03)00210-5</ArticleId><ArticleId IdType="pubmed">13678859</ArticleId></ArticleIdList></Reference><Reference><Citation>Roux S., Colasante C., Saint Cloment C., Barbier J., Curie T., Girard E., Molg&#xf3; J., Br&#xfb;let P. Internalization of a GFP-tetanus toxin C-terminal fragment fusion protein at mature mouse neuromuscular junctions. Mol. Cell Neurosci. 2005;30:572&#x2013;582. doi: 10.1016/j.mcn.2005.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2005.05.008</ArticleId><ArticleId IdType="pubmed">16456925</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrando-Grabulosa M., Casas C., Aguilera J. The C-terminal domain of tetanus toxin protects motor neurons against acute excitotoxic damage on spinal cord organotypic cultures. J. Neurochem. 2013;124:36&#x2013;44. doi: 10.1111/jnc.12062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.12062</ArticleId><ArticleId IdType="pubmed">23106494</ArticleId></ArticleIdList></Reference><Reference><Citation>Herreros J., Ng T., Schiavo G. Lipid rafts act as specialized domains for tetanus toxin binding and internalization into neurons. Mol. Biol. Cell. 2001;12:2947&#x2013;2960. doi: 10.1091/mbc.12.10.2947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.12.10.2947</ArticleId><ArticleId IdType="pmc">PMC60147</ArticleId><ArticleId IdType="pubmed">11598183</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpern J.L., Loftus A. Characterization of the receptor-binding domain of tetanus toxin. J. Biol. Chem. 1993;268:11188&#x2013;11192.</Citation><ArticleIdList><ArticleId IdType="pubmed">8388386</ArticleId></ArticleIdList></Reference><Reference><Citation>Benson M.A., Fu Z., Kim J.J., Baldwin M.R. Unique ganglioside recognition strategies for clostridial neurotoxins. J. Biol. Chem. 2011;286:34015&#x2013;34022. doi: 10.1074/jbc.M111.272054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.272054</ArticleId><ArticleId IdType="pmc">PMC3190786</ArticleId><ArticleId IdType="pubmed">21849494</ArticleId></ArticleIdList></Reference><Reference><Citation>Yavin E., Nathan A. Tetanus toxin receptors on nerve cells contain a trypsin-sensitive component. Eur. J. Biochem. 1986;154:403&#x2013;407. doi: 10.1111/j.1432-1033.1986.tb09412.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1432-1033.1986.tb09412.x</ArticleId><ArticleId IdType="pubmed">3943536</ArticleId></ArticleIdList></Reference><Reference><Citation>Herreros J., Lalli G., Montecucco C., Schiavo G. Tetanus toxin fragment C binds to a protein present in neuronal cell lines and motor neurons. J. Neurochem. 2000;74:1941&#x2013;1950. doi: 10.1046/j.1471-4159.2000.0741941.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2000.0741941.x</ArticleId><ArticleId IdType="pubmed">10800937</ArticleId></ArticleIdList></Reference><Reference><Citation>Deinhardt K., Salinas S., Verastegui C., Watson R., Worth D., Hanrahan S., Bucci C., Schiavo G. Rab5 and Rab7 control endocytic sorting along the axonal retrograde transport pathway. Neuron. 2006;52:293&#x2013;305. doi: 10.1016/j.neuron.2006.08.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2006.08.018</ArticleId><ArticleId IdType="pubmed">17046692</ArticleId></ArticleIdList></Reference><Reference><Citation>Cha&#xef;b-Oukadour I., Gil C., Aguilera J. The C-terminal domain of the heavy chain of tetanus toxin rescues cerebellar granule neurones from apoptotic death: Involvement of phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways. J. Neurochem. 2004;90:1227&#x2013;1236. doi: 10.1111/j.1471-4159.2004.02586.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2004.02586.x</ArticleId><ArticleId IdType="pubmed">15312177</ArticleId></ArticleIdList></Reference><Reference><Citation>Cha&#xef;b-Oukadour I., Gil C., Rodr&#xed;guez-Alvarez J., Ortega A., Aguilera J. Tetanus toxin H(C) fragment reduces neuronal MPP+ toxicity. Mol. Cell Neurosci. 2009;41:297&#x2013;303. doi: 10.1016/j.mcn.2009.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2009.03.006</ArticleId><ArticleId IdType="pubmed">19344769</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendieta L., Venegas B., Moreno N., Patricio A., Mart&#xed;nez I., Aguilera J., Limon I.D. The carboxyl-terminal domain of the heavy chain of tetanus toxin prevents dopaminergic degeneration and improves motor behavior in rats with striatal MPP(+)-lesions. Neurosci. Res. 2009;65:98&#x2013;106. doi: 10.1016/j.neures.2009.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neures.2009.06.001</ArticleId><ArticleId IdType="pubmed">19523997</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliv&#xe1;n S., Calvo A.C., Rando A., Herrando-Grabulosa M., Manzano R., Zaragoza P., Tizzano E.F., Aquilera J., Osta R. Neuroprotective Effect of Non-viral Gene Therapy Treatment Based on Tetanus Toxin C-fragment in a Severe Mouse Model of Spinal Muscular Atrophy. Front. Mol. Neurosci. 2016;9:76. doi: 10.3389/fnmol.2016.00076.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2016.00076</ArticleId><ArticleId IdType="pmc">PMC4995219</ArticleId><ArticleId IdType="pubmed">27605908</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo A.C., Moreno-Igoa M., Mancuso R., Manzano R., Oliv&#xe1;n S., Mu&#xf1;oz M.J., Penas C., Zaragoza P., Navarro X., Osta R. Lack of a synergistic effect of a non-viral ALS gene therapy based on BDNF and a TTC fusion molecule. Orphanet J. Rare Dis. 2011;6:10. doi: 10.1186/1750-1172-6-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1172-6-10</ArticleId><ArticleId IdType="pmc">PMC3072305</ArticleId><ArticleId IdType="pubmed">21418619</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Igoa M., Calvo A.C., Penas C., Manzano R., Oliv&#xe1;n S., Mu&#xf1;oz M.J., Mancuso R., Zaragoza P., Aguilera J., Navarro X., et al. Fragment C of tetanus toxin, more than a carrier. Novel perspectives in non-viral ALS gene therapy. J. Mol. Med. 2010;88:297&#x2013;308. doi: 10.1007/s00109-009-0556-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-009-0556-y</ArticleId><ArticleId IdType="pubmed">19921501</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Igoa M., Calvo A.C., Ciriza J., Mu&#xf1;oz M.J., Zaragoza P., Osta R. Non-viral gene delivery of the GDNF, either alone or fused to the C-fragment of tetanus toxin protein, prolongs survival in a mouse ALS model. Restor. Neurol. Neurosci. 2012;30:69&#x2013;80. doi: 10.3233/RNN-2011-0621.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/RNN-2011-0621</ArticleId><ArticleId IdType="pubmed">22124037</ArticleId></ArticleIdList></Reference><Reference><Citation>Gil C., Chaib-Oukadour I., Blasi J., Aguilera J. HC fragment (C-terminal portion of the heavy chain) of tetanus toxin activates protein kinase C isoforms and phosphoproteins involved in signal transduction. Biochem. J. 2001;356 Pt 1:97&#x2013;103. doi: 10.1042/bj3560097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bj3560097</ArticleId><ArticleId IdType="pmc">PMC1221816</ArticleId><ArticleId IdType="pubmed">11336640</ArticleId></ArticleIdList></Reference><Reference><Citation>Gil C., Chaib-Oukadour I., Aguilera J. C-terminal fragment of tetanus toxin heavy chain activates Akt and MEK/ERK signalling pathways in a Trk receptor-dependent manner in cultured cortical neurons. Biochem. J. 2003;373 Pt 2:613&#x2013;620. doi: 10.1042/bj20030333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bj20030333</ArticleId><ArticleId IdType="pmc">PMC1223507</ArticleId><ArticleId IdType="pubmed">12710887</ArticleId></ArticleIdList></Reference><Reference><Citation>Sozbilen M.C., Ozturk M., Kaftan G., Dagci T., Ozyalcin H., Armagan G. Neuroprotective Effects of C-terminal Domain of Tetanus Toxin on Rat Brain Against Motorneuron Damages After Experimental Spinal Cord Injury. Spine. 2018;43:E327&#x2013;E333. doi: 10.1097/BRS.0000000000002357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BRS.0000000000002357</ArticleId><ArticleId IdType="pubmed">28767631</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein J.D., Jin L.I.N., Dykes-Hoberg M., Kuncl R.W. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc. Natl. Acad. Sci. USA. 1993;90:6591&#x2013;6595. doi: 10.1073/pnas.90.14.6591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.90.14.6591</ArticleId><ArticleId IdType="pmc">PMC46978</ArticleId><ArticleId IdType="pubmed">8393571</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraiuolo L., Kirby J., Grierson A.J., Sendtner M., Shaw P.J. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2011;7:616&#x2013;630. doi: 10.1038/nrneurol.2011.152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.152</ArticleId><ArticleId IdType="pubmed">22051914</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein J.D., Martin L.J., Kuncl R.W. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N. Engl. J. Med. 1992;326:1464&#x2013;1468. doi: 10.1056/NEJM199205283262204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199205283262204</ArticleId><ArticleId IdType="pubmed">1349424</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein J.D., Van Kammen M., Levey A.I., Martin L.J., Kuncl R.W. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann. Neurol. 1995;38:73&#x2013;84. doi: 10.1002/ana.410380114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410380114</ArticleId><ArticleId IdType="pubmed">7611729</ArticleId></ArticleIdList></Reference><Reference><Citation>Fray A.E., Ince P.G., Banner S.J., Milton I.D., Usher P.A., Cookson M.R., Shaw P.J. The expression of the glial glutamate transporter protein EAAT2 in motor neuron disease: An immunohistochemical study. Eur. J. Neurosci. 1998;10:2481&#x2013;2489. doi: 10.1046/j.1460-9568.1998.00273.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1460-9568.1998.00273.x</ArticleId><ArticleId IdType="pubmed">9767379</ArticleId></ArticleIdList></Reference><Reference><Citation>Foran E., Trotti D. Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis. Antioxid. Redox Signal. 2009;11:1587&#x2013;1602. doi: 10.1089/ars.2009.2444.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2009.2444</ArticleId><ArticleId IdType="pmc">PMC2842587</ArticleId><ArticleId IdType="pubmed">19413484</ArticleId></ArticleIdList></Reference><Reference><Citation>Matyja E., Naga&#x144;ska E., Taraszewska A., Rafatowska J. The mode of spinal motor neurons degeneration in a model of slow glutamate excitotoxicity in vitro. Folia Neuropathol. 2005;43:7&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">15827885</ArticleId></ArticleIdList></Reference><Reference><Citation>Matyja E., Taraszewska A., Naga&#x144;ska E., Rafa&#x142;owska J. Autophagic degeneration of motor neurons in a model of slow glutamate excitotoxicity in vitro. Ultrastruct. Pathol. 2005;29:331&#x2013;339. doi: 10.1080/01913120500214333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01913120500214333</ArticleId><ArticleId IdType="pubmed">16257859</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>